SCHEMBL9416764

SCHEMBL9416764

COC(=O)C(OC)(OC)C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.42
ALDH1A1 P00352 3/20 0.39
KCNN4 O15554 1/20 0.37
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
TSHR P16473 3/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
HCAR2 Q8TDS4 1/20 0.33
SRC P12931 1/20 0.33
HSD17B10 Q99714 1/20 0.30
MGAM O43451 1/20 0.30
GAA P10253 1/20 0.30
SI P14410 1/20 0.30
MGAM2 Q2M2H8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9402444 0.87 DGAT1 (0.34) DGAT1ALDH1A1KCNN4MEN1LMNA
SCHEMBL28668019 0.85 ALDH1A1 (0.40) DGAT1ALDH1A1KCNN4MEN1LMNA
SCHEMBL9416745 0.83 DGAT1 (0.36) DGAT1ALDH1A1KCNN4MEN1LMNA
SCHEMBL11496818 0.75 SRC (0.50) ALDH1A1KCNN4MAPTTSHRSRC
SCHEMBL788497 0.73 DGAT1 (0.42) DGAT1ALDH1A1KCNN4TSHRKEAP1
SCHEMBL8096308 0.72 DGAT1 (0.46) DGAT1ALDH1A1KCNN4MAPTTSHR
SCHEMBL5960637 0.71 ALDH1A1 (0.39) DGAT1ALDH1A1KCNN4MEN1LMNA
SCHEMBL2463205 0.71 MEN1 (0.42) DGAT1ALDH1A1KCNN4MEN1LMNA
SCHEMBL194990 0.71
SCHEMBL12121537 0.71 DGAT1 (0.46) DGAT1ALDH1A1KCNN4TSHRKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4046817-A Method of synthesis of pyrogallol IMC CHEMICAL GROUP, INC. (US) 1977-09-06 US claimed
US-8846686-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-30 US disclosed
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-11 US disclosed
CN-101475450-B Method for preparing pyrogallic acid with glyoxaline as gallic acid decarboxylation catalyst UNIV NANJING FORESTRY 2011-07-27 CN disclosed
CN-101475450-A Method for preparing pyrogallic acid with glyoxaline as gallic acid decarboxylation catalyst UNIV NANJING AGRICULTURAL (CN) 2009-07-08 CN disclosed
US-5292937-A Use of malonic acid derivative compounds for retarding plant growth RHONE-POULENC INC. (US) 1994-03-08 US disclosed
US-5123951-A Ethylene response inducing agent and malonic acid derivative RHONE-POULENC NEDERLAND B.V. (NL) 1992-06-23 US disclosed
US-4092351-A Method of synthesis of 4,5,6-trihydroxyisophthalic acid IMC CHEMICAL GROUP, INC. (US) 1978-05-30 US disclosed
US-4046817-A Method of synthesis of pyrogallol IMC CHEMICAL GROUP, INC. (US) 1977-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130089625-A1 Compounds Useful as Inhibitors of ATR Kinase ATR, CHEK1, MAP3K1 DGAT1 3586/4885ALDH1A1 3886/4885KCNN4 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.